Covaxin 81% Effective Against COVID-19 UK Strain In Phase-3 Trials

Indian pharmaceutical giant Bharat Biotech has claimed 81% efficacy against COVID-19 for its vaccine 'Covaxin'. Releasing the phase three clinical data of the vaccine on March 3, the company claimed the vaccine of being effective against the UK variants of the virus. While peer reviews are still awaited, the developer conducted clinical trials on over 25,800 people. Reportedly, Indian drug regulator DCGI earlier approved the Covaxin for emergency use authorization in January 2021.